Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has issued an update.
Lytix Biopharma AS has reminded investors that the subscription period for its subsequent offering of up to 3,333,333 new shares at NOK 9.00 per share, aiming to raise as much as NOK 30 million, expires today at 16:30 CET. Investors must submit or register subscription forms in time, as any unused, non-tradeable subscription rights will lapse without compensation.
The capital raise follows the company’s earlier disclosures and is conducted on the basis of a national prospectus, with DNB Carnegie acting as manager and Thommessen as legal advisor. The transaction is designed to provide additional funding for Lytix’s clinical-stage oncology pipeline, potentially strengthening its financial position as it advances its novel immuno-oncology candidates in a competitive biotech landscape.
More about Lytix Biopharma AS
Lytix Biopharma AS, based in Oslo, is a clinical-stage biotech company developing cancer immunotherapies built on host-defense peptide-derived molecules. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule designed to boost anti-cancer immunity, supported by a broader pipeline targeting multiple tumour types as mono- or combination therapies.
Average Trading Volume: 78,176
Current Market Cap: NOK714.8M
For a thorough assessment of 6BG stock, go to TipRanks’ Stock Analysis page.